complementary-DNA microarray study identified a gene-expression signature that-when used to cluster normal karyotype patients-separated them into two prognostically relevant subgroups. We sought the first independent validation of the prognostic value of this signature.
Using oligonucleotide microarrays to measure gene expression in samples from uniformly treated adults with karyotypically normal AML, we performed cluster analysis based on the previously identified signature. We also developed a well-defined classification rule using the signature to predict outcome for individual patients. Cluster analysis confirmed the prognostic utility of the signature: patient clusters differed in overall (P=0.001) and disease-free (P=0.001)
survival. The signature-based classifier identified groups with differences in overall (P=0.02) and disease-free (P=0.05) survival. A strong association of the outcome classifier with the prognostically adverse FLT3 internal tandem duplication (FLT3 ITD) potentially explained the prognostic significance of the signature. However, in the subgroup of patients without FLT3 ITD there was a moderate difference in survival for the classifier-derived groups. Our analysis confirms the applicability of the gene-expression profiling strategy for outcome prediction in cytogenetically normal AML. ) and/or overexpression (e.g., BAALC 13, 14, 19 and ERG 20 ) of distinct genes involved in tissue homeostatic regulatory pathways, and it is likely that other aberrantly expressed genes (e.g., EVI1
21
) will be added to this list in the future. Because these biomarkers are often not mutually exclusive, the prognostic weight of each is affected by the concurrent presence of the others. 13, 14, 16, 20 Thus, rather than performing multiple assays testing for a restricted number of currently known prognostic biomarkers, gene-expression profiling was explored as a strategy to capture a global view of the molecular heterogeneity of cytogenetically normal AML. 22, 23 The goal of these studies has been to recognize characteristic patterns of gene activation and silencing, the so-called "expression signatures", that can identify subsets of patients with different outcomes. Although intriguing, the hitherto reported results remain preliminary and require independent validation. [24] [25] [26] Recently, Bullinger et al. 22 reported for the first time a complementary-DNA (cDNA) microarray-based expression signature that separated AML patients with a normal karyotype into two cluster-derived prognostically relevant subgroups. In the current study, we applied this signature to the gene-expression profiles of a different group of AML patients with a 
Gene-expression profiling
Pretreatment blood samples were analyzed using Affymetrix U133 plus 2.0 GeneChips (Affymetrix, Santa Clara, CA). Total RNA extraction, double-stranded cDNA preparation, and biotinylated RNA in vitro transcription, labeling and hybridization to the U133 plus 2.0
GeneChip were previously described. 20 Scanned images were converted to CEL-files using Table 6 , www.ncbi.nlm.nih.gov/ geo/, accession #GSE425). We found 101 named genes from this signature on the Affymetrix U133 plus 2.0 Genechip, represented by 256 probe sets. Of the 256 probe sets, 157 were expressed (i.e., received an Affymetrix "Present" call) in 25% or more of our patient specimens, resulting in 81 of the 101 genes being represented among these 157 probe sets (Supplementary Table 1 ). The log 2 MBEI values of these 157 probe sets comprised the prognostic molecular signature we used for validation purposes (hereafter referred to as the "Bullinger validation signature").
Statistical Analysis
Hierarchical cluster analysis 29 was performed on patient specimens with respect to the "Bullinger validation signature". Expression values for each probe set were median-centered only.
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Page 8 of 30 8 across patients prior to clustering. Average linkage was used and the dissimilarity measure was one minus correlation. We cut the resulting dendrogram at a height that created two clusters of specimens and tested for a difference in survival between the clusters using a permutation method based on the log-rank test (see supplementary material).
We investigated the ability of the "Bullinger validation signature" to predict poor or good outcome for individual patients using a class prediction algorithm, compound covariate prediction (CCP). 30 We used the "Bullinger validation signature" to compute a compound covariate (a linear combination of the log-expression values for the 157 probe sets) for each specimen in our data set. The weight of each probe set in the linear combination was taken to be the two-sample t statistic of the corresponding gene from Bullinger et al.'s gene-expression data comparing the cluster-based poor and good outcome groups within the subset of normal karyotype patients (data not shown).
For overall survival, patients were dichotomized into poor and good outcome classes based upon whether they died or were alive at last follow-up, respectively. This dichotomization is fitting since all currently living patients have been followed for at least 4.6 years and all patients who died did so within the first 3.6 years. A similar dichotomization was used for disease-free survival as all patients who relapsed (the poor outcome class) did so within 2.4 years and all patients currently in continuous complete remission (the good outcome class) have a follow-up time of at least 4.5 years. CCP was then performed using a leave-one-out crossvalidation. Of note, since genes and weights were completely specified by the previous geneexpression study, 22 the only step that was cross-validated in this analysis was the computation of the classification threshold. The patient to be predicted was removed from the analysis, the mean only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From 76806678-file00 Page 9 of 30 Page 9 of 30 9 compound covariate value for each class (i.e., poor and good outcome classes) among the remaining patients was computed and the classification threshold was defined as the midpoint of the means of these two classes. The outcome group for the left-out patient was predicted by comparing its compound covariate value to the classification threshold. We measured overall prediction accuracy and compared survival curves for the predicted outcome classes using a permutation method based on the log-rank test (see supplementary material).
Fisher's two-sided exact or Wilcoxon rank-sum tests were used to measure the association between predicted outcome groups and categorical or continuous pre-treatment clinical features, respectively. Proportional hazards models were fit for overall and disease-free survival using the predicted outcome group and FLT3 ITD status variables, both with and without their interaction term. The proportional hazards assumption was checked. All analyses were performed by the CALGB Statistical Center.
only.
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RESULTS

Prognostic significance of the "Bullinger validation signature" in AML with a normal karyotype
Patients were initially clustered with respect to expression of the "Bullinger validation signature". The resulting dendrogram contained two distinct clusters of specimens: cluster I, corresponding to the poor-, and cluster II, corresponding to the good-outcome group previously identified 22 ( Figure 1A ). Cluster I patients had inferior overall survival (P=0.001; Figure 1B ) and disease-free survival (P=0.001; Figure 1C ), with estimated 5-year overall and disease-free survival rates of 28% and 24% compared with 64% and 60%, respectively, for cluster II patients.
Outcome prediction by a classifier based on the "Bullinger validation signature"
Validation of a signature must move beyond assessing whether the same genes are prognostic in a subsequent study; a well-defined classifier needs to be developed that can be applied to individual patients in future studies for assessment of the signature's predictive value and clinical relevance. 31 
than the predicted good outcome class. The difference in overall survival between the two classes was significant (P=0.02; Figure 2A ). Patients in the predicted good outcome class had an estimated 5-year survival rate of 56% compared with only 30% for the patients in the predicted poor outcome class. The overall prediction accuracy for outcome class was 62.5% ( Figure 2C ).
For disease-free survival, 24 patients were predicted to have poor outcome and 30 patients good outcome. Differences in pre-treatment features between the two disease-free survival predicted outcome classes were similar to those identified for overall survival (Table 2 ).
There was a significant difference in disease-free survival between CCP predicted outcome classes (P=0.05; Figure 2B ), with estimated 5-year disease-free survival rates of 50% and 29%
for the predicted good and poor outcome classes, respectively. The overall prediction accuracy for outcome class was 59.3% ( Figure 2D ).
A strong association was observed between the signature-based outcome classifications and FLT3 ITD status. Of the patients constituting the predicted good outcome class, less than 20% were FLT3 ITD-positive while 67% of the patients in the predicted poor outcome class were FLT3 ITD-positive (Tables 1 and 2 ). Because of this association and the well-established prognostic importance of FLT3 ITD, we examined the impact of the predicted outcome classes on outcome when adjusting for FLT3 ITD status. Multivariable models for overall and diseasefree survival showed that the signature-based class membership did not predict outcome independently of FLT3 ITD status (P=0.69 and P=0.82 for overall and disease-free survival, respectively). However, there was a moderate interaction effect between the two variables with respect to overall survival (P=0.10), and a significant interaction effect with respect to diseasefree survival (P=0.03). While in patients with FLT3 ITD, the signature-based classification failed to result in an appropriate separation of the outcome curves of the poor and good outcome predicted classes ( Figure 3A ), in patients with wild-type FLT3, the signature-based classification produced a moderate separation in curves ( Figure 3B ). This suggested that the signature-based classifier may be able to distinguish a subset of patients with poor outcome when analysis is restricted to those with wild-type FLT3 and normal cytogenetics.
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DISCUSSION
We successfully confirmed, using a different microarray platform, the prognostic significance of the expression signature identified by Bullinger et al. 22 in karyotypically normal AML patients. Cluster analysis of our patients with respect to expression of the "Bullinger validation signature" resulted in two distinct clusters with differences in survival. Furthermore, we developed a well-defined classifier based on the signature that predicts dichotomized outcome for individual patients. The prognostic significance of the "Bullinger validation signature" was maintained with the shift in analysis strategies as the predicted outcome classes exhibited a significant difference in both overall and disease-free survival.
Our use of a classifier to validate the prognostic significance of the expression signature complements the cluster-based results of the previous study. Bullinger et al. 22 acknowledged the limitations of cluster-based classification and successfully implemented a class prediction algorithm (the PAM method of nearest shrunken centroids) for their whole patient group that included both cytogenetically normal and abnormal patients, but were unable to maintain prognostic significance in the subset with a normal karyotype. 22 Their lack of success in the subset of karyotypically normal patients was likely not due to the use of a different prediction algorithm but, rather, to inadequate sample size as testing of their initial results was performed on only 22 AML patients with a normal karyotype. 22 In contrast, as the expression signature was already defined using data from the earlier study, 22 we did not have to divide our 64 patients into separate training and test sets but could treat the whole patient cohort as a validation set.
Furthermore, the median duration of follow-up for survivors in our patient group (4.7 years) was considerably longer than that of less than 2 years reported in the Bullinger et al. study. Confirming the prognostic significance of the "Bullinger validation signature" in our study is noteworthy not only because the two studies included patients treated on different protocols at different institutions, but also because different microarray platforms were used. The previous study employed a common reference design using cDNA arrays manufactured by the Stanford Functional Genomics Facility 22 while we used the commercially available Affymetrix U133 plus 2.0 GeneChip. We were unable to create a perfect representation of the signature identified in the previous study using our microarray data because the original signature contained expressed sequence tags that we could not match to probe sets on the Affymetrix oligonucleotide array. Furthermore, some named genes in the original signature were represented by multiple probe sets on the oligonucleotide array and therefore appeared more than once in the validation signature. Even with this lack of precision in our representation of the original signature, the validation signature was robust enough so that its prognostic value was maintained in our patient set.
While we confirmed the expression signature reported by Bullinger et al., 22 the prediction accuracy of the classifier for dichotomized outcome classes was modest for both overall and disease-free survival. The outcome of approximately 40% of the patients could not be correctly predicted. Despite this limitation and the association of the signature-based classifier with FLT3
ITD status, the classifier showed some ability to identify a subset of patients with wild-type FLT3 who fare poorly. Furthermore, while Bullinger et al. 22 also noted a strong association of FLT3 status with the two major clusters of normal karyotype patients identified by the expression signature, the prognostic significance of the signature was shown to be independent of FLT3 when considering the whole patient set (including patients with cytogenetic aberrations).
For
In conclusion, despite some limitations of the signature-based classifier, our analysis validates the use of the gene-expression profiling strategy for outcome prediction in cytogenetically normal AML. The goal of future studies is to refine this strategy and assess whether it is possible to identify different classifiers that predict outcome for individual patients with cytogenetically normal AML more accurately than the one based on the only hitherto reported expression signature with prognostic significance.
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APPENDIX
The following Cancer and Leukemia Group B institutions, principal investigators, and cytogeneticists participated in this study:
North Shore-Long Island Jewish Health System, Manhasset, NY: Daniel R. Budman and Prasad
